Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Immune Network
;
: 3-2020.
Artigo
em Inglês
| WPRIM
| ID: wpr-811179
ABSTRACT
Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic agents, are now approved by the Food and Drug Administration for treatment of various types of cancer. However, the therapeutic efficacy of ICIs varies among patients and cancer types. Moreover, most patients do not develop durable antitumor responses after ICI therapy due to an ephemeral reversal of T-cell dysfunction. As co-stimulatory receptors play key roles in regulating the effector functions of T cells, activating co-stimulatory pathways may improve checkpoint inhibition efficacy, and lead to durable antitumor responses. Here, we review recent advances in our understating of co-stimulatory receptors in cancers, providing the necessary groundwork for the rational design of cancer immunotherapy.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
United States Food and Drug Administration
/
Linfócitos T
/
Receptores Coestimuladores e Inibidores de Linfócitos T
/
Imunoterapia
Limite:
Humanos
Idioma:
Inglês
Revista:
Immune Network
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS